标题
Targeting the RAS oncogene
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 17, Issue 5, Pages 507-531
出版商
Informa Healthcare
发表日期
2013-01-30
DOI
10.1517/14728222.2013.764990
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ridaforolimus
- (2013) Drugs in research & development
- Abstract 3555: Anti-tumor activity of CAL-101, a potent selective inhibitor of the p110Δ isoform of PI3K, in models of human glioblastoma
- (2012) Adam Kashishian et al. CANCER RESEARCH
- Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor
- (2012) Darrin D. Stuart et al. CANCER RESEARCH
- Abstract 3737: The PI3K/mTOR inhibitor PWT33597 regresses 786-0 renal xenografts
- (2012) Marie O'Farrell et al. CANCER RESEARCH
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
- (2012) Y. Su et al. CLINICAL CANCER RESEARCH
- Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer
- (2012) Daniel Laheru et al. INVESTIGATIONAL NEW DRUGS
- Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
- (2012) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models
- (2012) Xianhua Wu et al. Journal of Translational Medicine
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
- (2012) Tim Eisen et al. LANCET ONCOLOGY
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases.
- (2012) T. C. K. Chan et al. MOLECULAR CANCER THERAPEUTICS
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treating metastatic soft-tissue or bone sarcomas – potential role of ridaforolimus
- (2012) Vicki Keedy OncoTargets and Therapy
- Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
- (2011) Qing Dong et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- PI3K inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma
- (2011) S. A. Meadows et al. BLOOD
- Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species
- (2011) Vipul Kumar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells
- (2011) C. Babij et al. CANCER RESEARCH
- Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
- (2011) C. Santiskulvong et al. CLINICAL CANCER RESEARCH
- Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
- (2011) R. Mallon et al. CLINICAL CANCER RESEARCH
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
- (2011) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors
- (2011) Zhihong Chen et al. ENDOCRINE-RELATED CANCER
- The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion
- (2011) Sze Ki Luk et al. EUROPEAN JOURNAL OF CANCER
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
- (2011) Bert H. O'Neil et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
- (2011) J. Yuan et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
- (2011) S. V. Bhagwat et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
- (2011) A. S. Little et al. Science Signaling
- Two Faces of Protein Kinase Cδ: The Contrasting Roles of PKCδ in Cell Survival and Cell Death
- (2011) Alakananda Basu et al. TheScientificWorldJOURNAL
- C-Raf Is Required for the Initiation of Lung Cancer by K-Ras G12D
- (2011) Florian A. Karreth et al. Cancer Discovery
- PI3K/p110 is a novel therapeutic target in multiple myeloma
- (2010) H. Ikeda et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
- (2010) Kihyun Kim et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
- (2010) Elias Jabbour et al. CANCER
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
- (2010) Y. N. V. Gopal et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Everolimus
- (2010) P. J. Houghton CLINICAL CANCER RESEARCH
- Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
- (2010) Matthias Drosten et al. EMBO JOURNAL
- Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition
- (2010) Nicolas Charette et al. Molecular Cancer
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- A complex interplay between Akt, TSC2 and the two mTOR complexes: Figure 1
- (2009) Jingxiang Huang et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
- (2009) J.-L. Harousseau et al. BLOOD
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors
- (2009) Apostolia Maria Tsimberidou et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
- (2009) Claudia Scholl et al. CELL
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer
- (2009) J. A. Sparano et al. CLINICAL CANCER RESEARCH
- Modelling oncogenic Ras/Raf signalling in the mouse
- (2009) Florian A Karreth et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- The PKB/AKT Pathway in Cancer
- (2009) Amancio Carnero CURRENT PHARMACEUTICAL DESIGN
- Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines
- (2009) Kathryn Balmanno et al. INTERNATIONAL JOURNAL OF CANCER
- NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
- (2009) T.-J. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
- (2009) Etienne Meylan et al. NATURE
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
- (2009) M. L. Sos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synthetic lethality: a framework for the development of wiser cancer therapeutics
- (2009) William G Kaelin Genome Medicine
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins
- (2008) B. B. Friday et al. CANCER RESEARCH
- PKCδ survival signaling in cells containing an activated p21Ras protein requires PDK1
- (2008) Shuhua Xia et al. CELLULAR SIGNALLING
- Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
- (2008) B. I. Rini CLINICAL CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats
- (2008) L. Goldberg et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K/Akt: getting it right matters
- (2008) T F Franke ONCOGENE
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More